Download PDF
Thromb Haemost 2010; 103(01): 11-12
DOI: 10.1160/TH09-10-0694
Editorial Focus
Schattauer GmbH

Glycoprotein inhibitors in patients on chronic anticoagulation: Safe enough or too much risk?

Francisco Marín
1   Derpartment of Cardiology, Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
,
Bárbara Bonacasa
1   Derpartment of Cardiology, Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
,
Mariano Valdés
1   Derpartment of Cardiology, Hospital Universitario Virgen de la Arrixaca, Universidad de Murcia, Murcia, Spain
› Author Affiliations
Further Information

Publication History

Received: 11 October 2009

Accepted after minor revision: 26 October 2009

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Rubboli A, Halperin JL. Pro: “Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/ or undergo percutaneous coronary intervention”. Thromb Haemost 2008; 100: 752-753.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Roldán V, Marín F. Contra: “Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recomended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary intervention”. Not for every body. Thromb Haemost 2008; 100: 754-755.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Fuster V, Rydén LE, Cannom DS. et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: 257-354.
    CrossrefPubMedGoogle Scholar
  • 4 Van der Werf F, Bax J, Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Tasf Force on the Management of ST-elevation Acute Myocardial Infarction of the European Society of Cardioloy. Eur Heart J 2008; 29: 2909-2945.
    CrossrefPubMedGoogle Scholar
  • 5 Karjalainen PP, Porela P, Ylitalo A. et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28: 726-732.
    CrossrefPubMedGoogle Scholar
  • 6 Ruiz-Nodar JM, Marín F, Hurtado JA. et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51: 818-825.
    CrossrefPubMedGoogle Scholar
  • 7 May AE, Geisler T, Gawaz M. Individualized anti-thrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb Haemost 2008; 99: 487-493.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Rao SV, O’Grady K, Pieper KS. et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-1206.
    CrossrefPubMedGoogle Scholar
  • 9 Mehran R, Pocock SJ, Stone GW. et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model form the ACUITY trial. Eur Heart J 2009; 30: 1457-1466.
    CrossrefPubMedGoogle Scholar
  • 10 Topol E, Byzova T, Plow E. Platelet GP IIb/IIIa blockers. Lancet 1999; 353: 227-231.
    CrossrefPubMedGoogle Scholar
  • 11 Patrono C, Baigent C, Hirsh J. et al. Antiplatelet drugs. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199S-233S.
    CrossrefPubMedGoogle Scholar
  • 12 Mehilli J, Kastrati A, Schuhlen H. et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627-3635.
    CrossrefPubMedGoogle Scholar
  • 13 Lahtela H, Karjalainen PP, Niemelä M. et al. Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment?. Thromb Haemost 2009; 102: 1227-1233.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Rubboli A, Halperin JL, Airaksinen KE. et al. Anti-thrombotic therapy in patients treated with oral anticoagulation undergoing coronary stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008; 40: 428-436.
    CrossrefPubMedGoogle Scholar
  • 15 Alexander K, Chen A, Newby L. et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress AD-verse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 2006; 114: 1380-1387.
    CrossrefPubMedGoogle Scholar
  • 16 Nikolsky E, Mehran R, Dangas G. et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28: 1936-1945.
    CrossrefPubMedGoogle Scholar
  • 17 Karjalainen PP, Vikman S, Niemelä M. et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008; 29: 1001-1010.
    CrossrefPubMedGoogle Scholar
  • 18 Manzano-Fernández S, Pastor FJ, Marín F. et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008; 134: 559-567.
    CrossrefPubMedGoogle Scholar
  • 19 Beyth RJ, Quinn LM, Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
    CrossrefPubMedGoogle Scholar
  • 20 Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 2007; 98: 980-987.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Lip GYH, Huber K, Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary inter-vention/stenting. A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventionss (EAPCI). Thromb Haemost 2010; 103: 13-28.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Burzotta F, De Vita M, Gu YL. et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J 2009; 30: 2193-2203.
    CrossrefPubMedGoogle Scholar
  • 23 De Luca G, Cassetti E, Verdoia M. et al. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: A meta-analysis of randomised trials. Thromb Haemost 2009; 102: 428-436.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Stone GW, White HD, Ohman EM. et al. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369: 907-919.
    CrossrefPubMedGoogle Scholar